Rosuvastatin and progression of atherosclerosis

References

• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet344, 1383–1389 (1994).
   PubMed Web of Science ®Google Scholar
• The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med.339, 1349–1357 (1998).
   PubMed Web of Science ®Google Scholar
• MRC/BHF Heart Protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet360, 7–22 (2002).
   PubMed Web of Science ®Google Scholar
• Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFcaps/Texcaps. AirForce/Texas Coronary Atherosclerosis Prevention Study. JAMA279, 1615–1622 (1998).
   PubMed Web of Science ®Google Scholar
• Sacks FM, Pfeffer MA, Moye LA et al.; Cholesterol and Recurrent Events Trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med.335, 1001–1009 (1996).
   PubMed Web of Science ®Google Scholar
• Shepherd J, Cobbe SM, Ford I et al.; West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med.333, 1301–1307 (1995).
   PubMed Web of Science ®Google Scholar
• Pedersen TR, Faergeman O, Kastelein JJ et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA294, 2437–2445 (2005).
   PubMed Web of Science ®Google Scholar
• LaRosa JC, Grundy SM, Waters DD et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med.352, 1425–1435 (2005).
   PubMed Web of Science ®Google Scholar
• Kapur NK. Rosuvastatin: a highly potent statin for the prevention and management of coronary artery disease. Expert Rev. Cardiovasc. Ther.5, 161–175 (2007).
   PubMedGoogle Scholar
• McKenney JM. Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks. Am. J. Cardiol.96, 60E–66E (2005).
   PubMed Web of Science ®Google Scholar
• Jones PH, Davidson MH, Stein EA et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am. J. Cardiol.92, 152–160 (2003).
   PubMed Web of Science ®Google Scholar
• Ballantyne CM. Clinical trial endpoints: angiograms, events, and plaque instability. Am. J. Cardiol.82, 5M–11M (1998).
   PubMedGoogle Scholar
• Brown BG, Zhao XQ, Chait A et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med.345, 1583–1592 (2001).
   PubMed Web of Science ®Google Scholar
• Ambrose JA, Tannenbaum MA, Alexopoulos D et al. Angiographic progression of coronary artery disease and the development of myocardial infarction. J. Am. Coll. Cardiol.12, 56–62 (1988).
   PubMed Web of Science ®Google Scholar
• Topol EJ, Nissen SE. Our preoccupation with coronary luminology. The dissociation between clinical and angiographic findings in ischemic heart disease. Circulation92, 2333–2342 (1995).
   PubMed Web of Science ®Google Scholar
• Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation96, 1432–1437 (1997).
   PubMed Web of Science ®Google Scholar
• Chambless LE, Heiss G, Folsom AR et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987–1993. Am. J. Epidemiol.146, 483–494 (1997).
   PubMed Web of Science ®Google Scholar
• Hodis HN, Mack WJ, LaBree L et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann. Intern. Med.128, 262–269 (1998).
   PubMed Web of Science ®Google Scholar
• O’Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr; Cardiovascular Health Study Collaborative Research Group. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N. Engl. J. Med.340, 14–22 (1999).
   PubMed Web of Science ®Google Scholar
• Amarenco P, Labreuche J, Lavallee P, Touboul PJ. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke35, 2902–2909 (2004).
   PubMed Web of Science ®Google Scholar
• Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on Atherosclerosis Progression In Familial Hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet357, 577–581 (2001).
   PubMed Web of Science ®Google Scholar
• Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation106, 2055–2060 (2002).
   PubMed Web of Science ®Google Scholar
• Crouse JR 3rd, Raichlen JS, Riley WA et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA297, 1344–1353 (2007).
   PubMed Web of Science ®Google Scholar
• Kastelein JJ, Akdim F, Stroes ES et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N. Engl. J. Med.358, 1431–1443 (2008).
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tuzcu EM, Schoenhagen P et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA291, 1071–1080 (2004).
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tuzcu EM, Schoenhagen P et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N. Engl. J. Med.352, 29–38 (2005).
   PubMed Web of Science ®Google Scholar
• Ridker PM, Cannon CP, Morrow D et al. C-reactive protein levels and outcomes after statin therapy. N. Engl. J. Med.352, 20–28 (2005).
   PubMed Web of Science ®Google Scholar
• Nissen SE, Nicholls SJ, Sipahi I et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA295, 1556–1565 (2006).
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Tuzcu EM, Sipahi I et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA297, 499–508 (2007).
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Raichlen JS, Nicholls SJ et al. Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography. a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden. Circulation117, 2458–2466 (2008).
   PubMed Web of Science ®Google Scholar
• Greenland P, LaBree L, Azen SP, Doherty TM, Detrano RC. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA291, 210–215 (2004).
   PubMed Web of Science ®Google Scholar
• Pletcher MJ, Tice JA, Pignone M, Browner WS. Using the coronary artery calcium score to predict coronary heart disease events: a systematic review and meta-analysis. Arch. Intern. Med.164, 1285–1292 (2004).
   PubMed Web of Science ®Google Scholar
• Shaw LJ, Raggi P, Schisterman E, Berman DS, Callister TQ. Prognostic value of cardiac risk factors and coronary artery calcium screening for all-cause mortality. Radiology228, 826–833 (2003).
   PubMed Web of Science ®Google Scholar
• Achenbach S, Ropers D, Pohle K et al. Influence of lipid-lowering therapy on the progression of coronary artery calcification: a prospective evaluation. Circulation106, 1077–1082 (2002).
   PubMed Web of Science ®Google Scholar
• Raggi P, Davidson M, Callister TQ et al.Aggressive versus moderate lipid-lowering therapy in hypercholesterolemic postmenopausal women: Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES). Circulation112, 563–571 (2005).
   PubMed Web of Science ®Google Scholar
• Schmermund A, Achenbach S, Budde T et al. Effect of intensive versus standard lipid-lowering treatment with atorvastatin on the progression of calcified coronary atherosclerosis over 12 months: a multicenter, randomized, double-blind trial. Circulation113, 427–437 (2006).
   PubMed Web of Science ®Google Scholar
• Achenbach S, Ropers D, Pohle FK et al. Detection of coronary artery stenoses using multi-detector CT with 16x0.75 collimation and 375 ms rotation. Eur. Heart J.26, 1978–1986 (2005).
   PubMed Web of Science ®Google Scholar
• Salm LP, Bax JJ, Jukema JW et al. Comprehensive assessment of patients after coronary artery bypass grafting by 16-detector-row computed tomography. Am. Heart J.150, 775–781 (2005).
   PubMed Web of Science ®Google Scholar
• Worthley SG, Helft G, Fuster V et al. Noninvasive in vivo magnetic resonance imaging of experimental coronary artery lesions in a porcine model. Circulation101, 2956–2961 (2000).
   PubMed Web of Science ®Google Scholar
• Fayad ZA, Nahar T, Fallon JT et al. In vivo magnetic resonance evaluation of atherosclerotic plaques in the human thoracic aorta: a comparison with transesophageal echocardiography. Circulation101, 2503–2509 (2000).
   PubMed Web of Science ®Google Scholar
• Corti R, Fayad ZA, Fuster V et al. Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high-resolution, noninvasive magnetic resonance imaging. Circulation104, 249–252 (2001).
   PubMed Web of Science ®Google Scholar
• Corti R, Fuster V, Fayad et al. Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years’ follow-up by high-resolution noninvasive magnetic resonance imaging. Circulation106, 2884–2887 (2002).
   PubMed Web of Science ®Google Scholar
• Corti R, Fuster V, Fayad ZA et al. Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging. J. Am. Coll. Cardiol.46, 106–112 (2005).
   PubMed Web of Science ®Google Scholar
• Underhill HR, Yuan C, Zhao XQ et al. Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial. Am. Heart J.155, 584 e581–e588 (2008).
   Google Scholar
• Kawasaki M, Sano K, Okubo M et al. Volumetric quantitative analysis of tissue characteristics of coronary plaques after statin therapy using three-dimensional integrated backscatter intravascular ultrasound. J. Am. Coll. Cardiol.45, 1946–1953 (2005).
   PubMed Web of Science ®Google Scholar
• Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteases, and cell death in human carotid plaques. Circulation103, 926–933 (2001).
   PubMed Web of Science ®Google Scholar